Skip to content
Quebec News Tribune – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Grants of Inducement Awards
November 6, 2026
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 3, 2026
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
October 18, 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 5, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 5, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
October 2, 2026
Spyre’s SPY003 Shows Positive Results in Ulcerative Colitis Trial
September 8, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
September 4, 2026
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
1
2
Next Page
→